How long should I wait before calling it a plateau?

Give it at least 4 weeks on a stable maintenance dose. Week-to-week weight swings of a pound or two are water and food volume, not fat. If the trend line has not moved in a month, and you are past the escalation phase, treat it as a real plateau and review the checklist in this article.

Does a plateau mean the drug has stopped working?

Usually not. The drug is still suppressing appetite; you have reached the weight where your intake and your energy needs match again. In STEP 5, semaglutide 2.4 mg held a mean loss of 15.2% at week 104, almost identical to week 52. Holding the loss is the drug working.

Will switching from semaglutide to tirzepatide restart weight loss?

It can, but the evidence comes from people starting fresh, not from people switching after a plateau. In SURMOUNT-5, tirzepatide produced a mean loss of 20.2% versus 13.7% for semaglutide at week 72. The ADA rates switching agents as a lower-evidence option than escalating your current drug to its maximum dose.

Should I take a break from the drug to reset my body?

No. There is no trial evidence that a break restores the early rate of loss. There is strong evidence that stopping causes regain. In the STEP 1 extension, people who stopped semaglutide regained two-thirds of their lost weight within a year. Talk to your prescriber before changing anything.

Why did I stop losing while I was still on a starter dose?

The starter doses exist for tolerability, not for weight loss. Wegovy starts at 0.25 mg and reaches the 2.4 mg maintenance dose at week 17. Zepbound starts at 2.5 mg and can climb to 15 mg. A stall on a middle dose is a dose plateau, and the label already has a step for it.

Why Has My Weight Loss Plateaued on a GLP-1 Drug?

The short answer: A plateau on a GLP-1 drug is usually the drug reaching its expected ceiling, not the drug failing. In the two-year STEP 5 trial, semaglutide 2.4 mg weight loss flattened around week 60 and held near 15% through week 104. Tirzepatide keeps working longer, but it slows too: people in SURMOUNT-4 lost 20.9% by week 36 and only 5.5% more over the next 52 weeks. Before you blame the drug, check your dose, intake, sleep, and muscle mass.

What counts as a plateau, and when does it usually happen?

Weight loss on these drugs is front-loaded. The trial data show where the curve bends for each drug.

Semaglutide (Wegovy). In STEP 1, 1,961 adults lost a mean of 14.9% at week 68 on semaglutide 2.4 mg, versus 2.4% on placebo. In the two-year STEP 5 trial, the authors wrote that weight loss "appeared to plateau around week 60." Mean loss was 15.6% at week 52 and 15.2% at week 104.
Tirzepatide (Zepbound). The Zepbound label reports SURMOUNT-1 losses at week 72 of 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, versus 3.1% on placebo. In SURMOUNT-4, people lost 20.9% in a 36-week lead-in. Those who stayed on tirzepatide lost a further 5.5% by week 88, for a total of 25.3%. Loss continues into the second year, but at a much slower pace.
Liraglutide (Saxenda). The Saxenda label reports a mean loss of 7.4% at week 56, versus 3% on placebo. The ceiling is lower, so the plateau arrives sooner and at a higher weight.

A practical definition: your weight has not moved for 4 or more weeks while you are on a stable maintenance dose. A flat month during dose escalation is not a plateau.

Is my metabolism slowing down?

Yes, and that is normal. A smaller body needs fewer calories. On top of that, the body often cuts resting energy use by more than the new size predicts. Researchers call this metabolic adaptation.

The clearest data come from an NIH study of 14 contestants from "The Biggest Loser". They lost a mean of 58.3 kg during the competition. Resting metabolic rate fell by 610 kcal per day. Six years later, after regaining a mean of 41.0 kg, metabolic adaptation was still 499 kcal per day below what their size predicted. That was extreme diet and exercise loss, not a GLP-1 trial, but the mechanism applies.

GLP-1 drugs work by cutting intake. They do not cancel adaptation. Early on, the gap between intake and expenditure is large. As you shrink and adapt, the gap closes. At some weight, intake and expenditure match again. That weight is the plateau.

Are you at a dose plateau or the drug's maximum?

Wegovy. The label escalates every 4 weeks: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then a maintenance dose of 2.4 mg (recommended) or 1.7 mg. If a step is not tolerated, the label says to consider delaying escalation for 4 weeks.
Zepbound. The label starts at 2.5 mg for 4 weeks, then 5 mg. The dose may rise in 2.5 mg increments after at least 4 weeks on the current dose. Maintenance doses are 5 mg, 10 mg, or 15 mg. The maximum is 15 mg. The label tells prescribers to "consider treatment response and tolerability when selecting the maintenance dosage." SURMOUNT-1 shows why dose matters: 15.0% on 5 mg versus 20.9% on 15 mg.
Saxenda. The label starts at 0.6 mg daily and increases by 0.6 mg each week until 3 mg. It also sets a checkpoint: evaluate at 16 weeks, and discontinue if the patient has not lost at least 4% of baseline weight.

If you stalled on 1 mg of semaglutide or 5 mg of tirzepatide, you are at a dose plateau. The label has a next step. If you have been on 2.4 mg of semaglutide for a year and are down about 15%, you are at the trial average. The drug is doing what it did in the trial. The ADA Standards of Care in Overweight and Obesity follow this order. Recommendation 2.17 says to escalate to the maximum dose first. Only if you are already at the maximum tolerable dose should you consider switching drugs, adding intensive lifestyle therapy, combining medications, or a surgical referral.

Is dietary creep or muscle loss stalling you?

Appetite suppression is strongest in the first months, when nausea and early fullness are also strongest. As those fade, portions grow back without you noticing. The trials did not test the drug alone. Every label says the drug is an adjunct to a reduced-calorie diet and increased physical activity. Log two weeks of meals. Most people find the creep.

Muscle loss is the second hidden factor. In the STEP 1 body composition substudy of 140 participants, semaglutide cut total fat mass by 19.3% and lean body mass by 9.7%. The share of lean mass rose by 3.0 percentage points, so the loss was mostly fat. But lean tissue burns more calories at rest than fat. Losing it brings the plateau closer. The ADA standards recommend 1.2 to 1.6 g of protein per kg of body weight per day and resistance training during active weight loss. Our guide to GLP-1 muscle loss covers how to measure and protect it.

Can poor sleep and stress stall weight loss?

Yes. A small NIH-funded crossover study published in Annals of Internal Medicine put 10 overweight adults on the same calorie-restricted diet for two 14-day periods, one with 8.5 hours in bed and one with 5.5 hours. Total weight loss was about 3 kg in both. With short sleep, fat loss fell from 1.4 kg to 0.6 kg, and fat-free mass loss rose from 1.5 kg to 2.4 kg. Hunger and ghrelin were higher on short sleep.

Stress works through a similar path. A 2025 review of the cortisol and obesity connection notes that chronic stress raises food intake, shifts preference toward high-calorie foods, and moves fat storage toward the abdomen. A GLP-1 drug blunts hunger. It does not fix a 5-hour night or chronic stress.

What are your options once you plateau?

Confirm it. Four or more flat weeks on a stable maintenance dose, not during escalation.
Check the dose against the label. If you are below the maximum and tolerating the drug, escalation is the ADA's first-line move.
Audit intake for two weeks. Look for liquid calories and portion growth.
Protect muscle. Hit the protein target and lift weights two or three times a week.
Fix sleep first, then stress. Sleep is the easier lever.
Ask about switching agents. In the 751-person SURMOUNT-5 trial, tirzepatide produced a mean loss of 20.2% at week 72 versus 13.7% for semaglutide. Those people started fresh; no trial has tested a switch after a plateau. Our comparison of GLP-1 medications lays out the trade-offs.
Do not stop. In the STEP 1 extension, people who stopped semaglutide regained 11.6 percentage points of body weight in one year, two-thirds of what they had lost. In SURMOUNT-4, people switched to placebo regained 14.0% between week 36 and week 88. ADA Recommendation 2.16 says to continue the medication after reaching your goal. Read what happens when you stop before you decide.

One more data point for people who feel slow from the start. A post hoc analysis of SURMOUNT-1 found that 82% of participants lost 5% or more by week 12. The late responders took a mean of 24.8 weeks to reach 5%. By week 72, 90% of those late responders had reached it. If you are on semaglutide, the Ozempic plateau guide on ozempic.md goes deeper on that drug.

The bottom line

A plateau after a year on a full dose is the expected shape of the curve. Semaglutide flattened around week 60 in STEP 5. Tirzepatide slowed sharply after week 36 in SURMOUNT-4. The fixable plateaus come from a middle dose, dietary creep, lost muscle, or short sleep. Work through those first, and do not stop the drug on your own.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Dose changes, switching medications, and stopping a GLP-1 drug are decisions for you and your prescriber.